

**Ref: ADL/SE/2024-25/78**  
**September 25, 2024**

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**BSE CODE: 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India Limited,**  
“Exchange Plaza”, Plot No. C/1,  
G Block Bandra - Kurla Complex,  
Bandra (East), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Ref: Clarification on announcement dated September 20, 2024 on US FDA inspection at the API manufacturing facility of the Company**

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is in continuation to the intimation dated September 20, 2024 and details asked by National Stock Exchange of India Limited (NSE) by email dated September 25, 2024, the information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is given below:

Name of the Authority	United States Food and Drug Administration (US FDA)
Nature and details of the action(s) taken, initiated or order(s) passed	United States Food and Drug Administration (US FDA) had conducted an inspection at API manufacturing facility of the Company at Plot No. E-22, MIDC, Tarapur, Maharashtra from 12 <sup>th</sup> to 20 <sup>th</sup> of September 2024.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	September 20, 2024
Details of the violation(s) / contravention(s) committed or alleged to be committed	On conclusion of the inspection, the company has received 7 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points.  There is no violation(s) / contravention(s) committed or alleged to be committed



**Aarti Drugs Limited**

**Manufacturers of : Bulk Drugs & Chemicals**

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible

There are no financial or material impacts as on date. On submission of reply to the observations, US FDA will issue the Establishment Inspection Report (EIR) concluding the inspection as Closed.

You are requested to take this reply on records.

Thanking you,

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

RUSHIKESH DEOLE

**COMPANY SECRETARY & COMPLIANCE OFFICER**

ICSI M. No.: F12932